LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that represents a promising target for the treatment of several metabolic diseases. Administration of recombinant wild type FGF21 to diabetic animals leads to a dramatic improvement in glycaemia and ameliorates other systemic measures of metabolic health. Here we report the pharmacologic outcomes observed in non-human primates upon administration of a recently described FGF21 analogue, LY2405319 (LY). Diabetic rhesus monkeys were treated subcutaneously with LY once daily for a period of seven weeks. The doses of LY used were 3, 9 and 50 mg/kg each delivered in an escalating fashion with washout measurements taken at 2, 4, 6 and 8 weeks following the final LY dose. LY therapy led to a dramatic and rapid lowering of several important metabolic parameters including glucose, body weight, insulin, cholesterol and triglyceride levels at all doses tested. In addition, we observed favorable changes in circulating profiles of adipokines, with increased adiponectin and reduced leptin indicative of direct FGF21 action on adipose tissue. Importantly, and for the first time we show that FGF21 based therapy has metabolic efficacy in an animal with late stage diabetes. While the glycemic efficacy of LY in this animal was partially attenuated its lipid lowering effect was fully preserved suggesting that FGF21 may be a viable treatment option even in patients with advanced disease progression. These findings support continued exploration of the FGF21 pathway for the treatment of metabolic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, despite weight loss and addition of medications, the disease progressed based on a continuous increase in HbA1c133.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [133]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, those in the intensive lifestyle arm with a history of cardiovascular event at baseline demonstrated a tendency for an increased risk of a subsequent cardiovascular event133”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [133]
In the citing paper
“Despite differential weight loss for over 10 years and improvements in many cardiovascular risk factors, including blood pressure and lipids, lifestyle change did not reduce cardiovascular events compared to diabetes support and education (control)133.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · cited 1×
“Recently our group and others have reported FGF21-induced regulation of the circulating levels and improved total body sensitivity to a multitude of other metabolic factors such as insulin, leptin and adiponectin highlighting one of the major mechanisms of FGF21 in vivo action [7,9,15,17].”
BackgroundSelf-citationXu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · cited 1×
“Indeed, administration of recombinant wild type FGF21 to diabetic rodents leads to a rapid and robust lowering of hyperglycemia, improvements in circulating/tissue lipid levels and reduced body weight [8–11].”
BackgroundFibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · cited 1×
“Recently our group and others have reported FGF21-induced regulation of the circulating levels and improved total body sensitivity to a multitude of other metabolic factors such as insulin, leptin and adiponectin highlighting one of the major mechanisms of FGF21 in vivo action [7,9,15,17].”
BackgroundSelf-citationIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847 · cited 1×
“One example of this new class of molecules is fibroblast growth factor 21 (FGF21) [3,4], which recently emerged as a promising agent able to simultaneously correct many if not all abnormalities in metabolically compromised animals [5–7].”
BackgroundThe metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · cited 7×
“Similar to the effects observed with administration of wild type FGF21 in rodents [7–9] and in primates [12,15], all monkeys experienced progressive weight loss during each dosing phase amounting to 12.”
BackgroundResultInfluentialSelf-citationLin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · cited 1×
“Given that FGF21 is unable to lower glucose in adiponectin null mice [22,23] one can surmise that the increase in adiponectin is explicitly required for FGF21s glycemic effect.”
BackgroundAdiponectin: mechanistic insights and clinical implications
Turer, A. T., & Scherer, P. E. (2012) · Diabetologia · doi:10.1007/s00125-012-2598-x · Cited by 632 · cited 1×
“Here we demonstrate that treatment with LY also leads to a rapid and robust induction of adiponectin, a known insulin sensitizer [21].”
BackgroundAn FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
Holland, W. L., Adams, A. C., Brozinick, J. T., Bui, H. H., Miyauchi, Y., Kusminski, C. M., Bauer, S. M., Wade, M., Singhal, E., Cheng, C. C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.019 · Cited by 535
Self-citationβKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism
Ding, X., Boney-Montoya, J., Owen, B. M., Bookout, A. L., Coate, K. C., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.002 · Cited by 403
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340 · cited 1×
“One example of this new class of molecules is fibroblast growth factor 21 (FGF21) [3,4], which recently emerged as a promising agent able to simultaneously correct many if not all abnormalities in metabolically compromised animals [5–7].”
Background
Cited by
Items 101–168 of 168
Caixeta, L. S., Giesy, S. L., Krumm, C. S., Perfield, J. W., Butterfield, A. M., & Boisclair, Y. R. (2019) · Journal of Dairy Science · doi:10.3168/jds.2019-16696 · Cited by 25
“On the other hand, FGF21 has been shown to reverse insulin resistance in rodents and primates suffering from type 2 diabetes or obesity (Xu et al., 2009a; Adams et al., 2013).”
BackgroundResultInfluentialHormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Chui, Z. S. W., Xue, Y., & Xu, A. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 21
“Indeed, preclinical studies in both rodents and monkeys have reproducibly observed the potent bene fi ts of FGF21 in ameliorating obesity and its related metabolic complications, including hyperglycaemia, dyslipi-daemia, MAFLD, atherosclerosis and cardiac disorders [49 – 53].”
BackgroundSelective Regulation of FGF19 and FGF21 Expression by Cellular and Nutritional Stress
SHIMIZU, M., MORIMOTO, H., Maruyama, R., Inoue, J., & Sato, R. (2015) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.61.154 · Cited by 21
Hepatic FGF21 production is increased in late pregnancy in the mouse
Cui, Y., Giesy, S. L., Hassan, M., Davis, K., Zhao, S., & Boisclair, Y. R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00554.2013 · Cited by 22
“Plasma FGF21 is often increased in individuals suffering from insulin resistance (50, 53), and FGF21 therapy reverses this condition (2, 16, 49).”
BackgroundGiragossian, C., Vage, C., Li, J., Pelletier, K. B., Piche‐Nicholas, N., Rajadhyaksha, M., Liras, J. L., Logan, A., Calle, R. A., & Weng, Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061713 · Cited by 21
“…in low-density lipoprotein cholesterol, apolipoproteins, fasting triglycerides, fasting insulin, and body weight, as well as dose-dependent elevations of high-density lipoprotein cholesterol and adiponectin (Adams et al., 2013; Gaich et al., 2013; Kharitonenkov et al., 2013; Smith et al., 2013).”
Current understanding and controversies on the clinical implications of fibroblast growth factor 21
Badakhshi, Y., & Jin, T. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1864278 · Cited by 21
“tein expression and formulation stability [81,105,108].”
BackgroundImpact of FGF21 on glycemic control
Strowski, M. Z. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0001 · Cited by 20
Krumm, C. S., Giesy, S. L., Caixeta, L. S., Perfield, J. W., Sauerwein, H., Moore, B. L., & Boisclair, Y. R. (2019) · Journal of Dairy Science · doi:10.3168/jds.2019-16695 · Cited by 22
Brooks, N. E., Hjortebjerg, R., Henry, B. E., List, E. O., Kopchick, J. J., & Berryman, D. E. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.08.003 · Cited by 19
FGF21 decreases food intake and body weight in obese Göttingen minipigs
Christoffersen, B. Ø., Straarup, E. M., Lykkegaard, K., Fels, J. J., Sass‐Ørum, K., Zhang, X., Raun, K., & Andersen, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13560 · Cited by 20
Dewal, R. S., Yang, F. T., Baer, L. A., Vidal, P., Hernández‐Saavedra, D., Seculov, N. P., Ghosh, A., Noé, F., Togliatti, O., Hughes, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108927 · Cited by 18
Exploring endocrine FGFs - structures, functions and biomedical applications
Phan, P., Ternier, G., Edirisinghe, O., & Kumar, T. K. S. (2024) · International Journal of Biochemistry and Molecular Biology · doi:10.62347/palk2137 · Cited by 18
Jiménez, V., Sacristan, V., Jambrina, C., Jaén, M. L., Casana, E., MUÑOZ, S. A., Marcó, S., Molas, M., García, M., Grass, I., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.023 · Cited by 16
“63 – 73 Continuous expression of AAV-derived native FGF21 also delivers a steady level of the protein, to avoid peak-to-trough pharmacokinetic variability associated with recombinant analog products that require frequent injections, which may lead to better treatment outcomes.”
Antonellis, P. J., Kharitonenkov, A., & Adams, A. C. (2014) · Journal of Animal Science · doi:10.2527/jas.2013-7076 · Cited by 17
Self-citationFGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems
Wang, J., Xing, L., Song, Y., Yang, Y., Zhang, Y., Ma, H., Su, B., Su, L., Ma, C., Liu, M., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.024 · Cited by 14
“LY2405319 is a synthetic peptide-based small molecule designed as an analogue of FGF21, often regarded as a metabolic modulator [183].”
Thompson, K. E., Guillot, M., Graziano, M. J., Mangipudy, R. S., & Chadwick, K. D. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115673 · Cited by 13
Mia, S., Siokatas, G., Sidiropoulou, R., Hoffman, M., Fragkiadakis, K., Markopoulou, E., Elesawy, M., Roy, R., Blair, S., Kuwabara, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102125 · Cited by 16
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 12
Reduced adiposity attenuates FGF21 mediated metabolic improvements in the Siberian hamster
Lewis, J. E., Samms, R. J., Cooper, S., Luckett, J., Perkins, A. C., Adams, A. C., Tsintzas, K., & Ebling, F. J. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-03607-x · Cited by 13
Self-citationResearch progress on the role of FGF21 in insulin resistance
Zhang, H., Zhu, R., Sun, Q., & Du, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1619462 · Cited by 16
Endocrine FGFs and their signaling in the brain: Relevance for energy homeostasis
Zangerolamo, L., Carvalho, M. U. W. B. D., Velloso, L. A., & Barbosa, H. C. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176248 · Cited by 11
Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
Sass‐Ørum, K., Tagmose, T. M., Olsen, J., Sjölander, A., Wahlund, P., Han, D., Vegge, A., Reedtz‐Runge, S., Wang, Z., Gao, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00391 · Cited by 12
Corbee, R. J., van Everdingen, D. L., Kooistra, H. S., & Penning, L. C. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.1086987 · Cited by 12
“LY (40, 49, 50) MI & MO: yes HU: no In all: yes MI & MO: yes HU: no HU &MO: yes”
BackgroundFibroblast Growth Factors: Roles and Emerging Therapeutic Applications
Ternier, G., Shahzad, K., Edirisinghe, O., Okoto, P. S., Alraawi, Z., Sonnaila, S., Phan, P., Adams, P. D., & Thallapuranam, S. (2025) · Current Drug Targets · doi:10.2174/0113894501351461250301072444 · Cited by 10
Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease
Zhou, X., Zhang, Y., & Wang, N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.764503 · Cited by 11
“In addition, the FGF21 analog LY2405319 (LY) with the half-life improving exerts an inhibitory effect on blood sugar and lipids, which indicates that the FGF21 pathway may be an ideal candidate for the treatment of metabolic diseases (Adams et al., 2013).”
BackgroundXia, M., Erickson, A., Yi, X., & Moreau, R. F. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.12.004 · Cited by 11
Zhao, Y., Liu, G., Kwok, S., Jones, B. R., Liu, J., Marchisin, D., Joyce, P., Peterson, J. E., & Shen, J. X. (2017) · Bioanalysis · doi:10.4155/bio-2017-0208 · Cited by 10
Solomon, T. P. J., Carter, S., Haus, J. M., Karstoft, K., von Holstein‐Rathlou, S., Nielsen, M. S., & Gillum, M. P. (2022) · PeerJ · doi:10.7717/peerj.12755 · Cited by 12
“…levels in ob/ob and db/db mice and ameliorate obesity and metabolic dysfunction in murine models of high fat diet-induced obesity as well as in obese and diabetic primates ( Kharitonenkov et al., 2005 ; Xu et al., 2009 ; Adams et al., 2013 ; Andersen et al., 2018 ; Wang et al., 2019 ) .”
Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis
Kwok, K. H. M., & Lam, K. S. L. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.145 · Cited by 9
An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Wu, P., Liu, Z., Jiang, X., & Fang, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191031104653 · Cited by 9
FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction
Diener, J. L., Mowbray, S. F., Huang, W.-J., Yowe, D. L., Xu, J., Caplan, S. L., Misra, A., Kapur, A., Shapiro, J., Ke, X., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab092 · Cited by 9
Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations
Stamou, M. I., Chiu, C. J., Jadhav, S. V., Lopes, V. F., Salnikov, K. B., Plummer, L., Lippincott, M. F., Lee, H., Seminara, S. B., & Balasubramanian, R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae118 · Cited by 8
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 9
“These lipid-handling processes in the liver are highly coordinated by multiple signaling pathways in association with multiple nuclear receptors (PPARs, ChREBP, FXR, LXR, Rev-ErbA, PGC1a, and SREBP1) and endocrine hormones (FGF21, insulin, glucagon, and leptin), and by interactions with multiple peripheral tissues to…”
InfluentialPathology and Therapeutic Significance of Fibroblast Growth Factors
Edirisinghe, O., Ternier, G., & Kumar, T. K. S. (2025) · Targets · doi:10.3390/targets3010005 · Cited by 10
“Moreover, in diabetic rhesus monkeys, subcutaneous administration of LY2405319 led to improvement in glycemic and lipid parameters (i.e., glucose level, insulin, cholesterol, and triglyceride levels were reduced) [299].”
Luo, C., Lv, N., Chang, Z., Qu, Q., & Huang, J. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.05.003 · Cited by 8
Jiang, X., Wu, Q., Opoku, Y. K., Zou, Y., Wang, D., Hu, C., & Ren, G. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13793 · Cited by 8
“Administration of FGF21 or its variants to rodents and rhesus monkeys with obesity and diabetes exerted strong anti-hyperglycemic and blood lipid-lowering effects.(8,10,11) Recently, the effects of FGF21 on the kidney have been widely explored.”
BackgroundBoisclair, Y. R., & Giesy, S. L. (2024) · Journal of Dairy Science · doi:10.3168/jds.2024-25799 · Cited by 9
Insights into the role of FGF21 in coronary heart disease
Zhang, Q.-Y., & Liu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136911 · Cited by 7
Girer, N. G., Rontoyanni, V. G., Joshi, A., Patrikeev, I., Murton, A. J., Porter, C. C., Motamedi, M., & Elferink, C. J. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000514 · Cited by 7
“Although recombinant wild-type FGF21 has performed poorly in clinical trials to date, other FGF21-analogs with greater thermostability have shown improved efficacy (Adams et al., 2013; Gaich et al., 2013).”
BackgroundHe, Y., Li, Y., Wei, Z., Zhang, X., Gao, J., Wang, X., Li, X., Wu, W., Li, W., Yi, X., et al. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2365 · Cited by 7
“[28] Adams AC, Halstead CA, Hansen BC, et al.”
BackgroundFibroblast growth factor-21 improves insulin action in nonlactating ewes
Lamb, C. L., Giesy, S. L., McGuckin, M. M., Perfield, J. W., Butterfield, A. M., Moniruzzaman, M., Haughey, N. J., McFadden, J. W., & Boisclair, Y. R. (2022) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00259.2021 · Cited by 7
Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics
Li, S., Song, Z., Fan, C., Zhang, W., Ma, T., Li, X., Zhang, Q., Zhao, M., Yu, T., & Li, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116306 · Cited by 6
Li, Z., Feng, S., Zhou, L., Liu, S., & Cheng, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.05.056 · Cited by 6
Zhen, J., Liu, S., Liu, L., Zheng, X., Zhao, G., Liang, J., Xu, A., Li, C., Ren, L., Wu, J., et al. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2500689 · Cited by 5
“In obese rodents and diabetic primates, administration of FGF21 resulted in beneficial metabolic effects including improved insulin sensitivity, significant weight reduction, and a decrease in both blood triglyceride and low-density lipoprotein cholesterol [3,4].”
Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021
She, Q.-Y., Li, L., Liu, M.-H., Tan, R.-Y., Zhong, Y.-W., Bao, J., & Xie, J.-D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011008 · Cited by 5
“Notably, in addition to traditional topics, such as the metabolic effects of FGF-21 on peripheral tissues (Adams et al., 2013b; De Sousa-Coelho et al., 2013; Holland et al., 2013; Kim et al., 2013; Lin et al., 2013; Emanuelli et al., 2014; Fisher et al., 2014; Jiang et al., 2014; Keipert et al.,…”
BackgroundInfluentialHuang, Y., Liu, B., Hu, C., & Lu, Y. (2025) · Protein & Cell · doi:10.1093/procel/pwaf027 · Cited by 6
“The anti-hyperglycemia effects of FGF21 have been replicated in diabetic monkey models (Adams et al., 2013; Kharitonenkov et al., 2007; Stanislaus et al., 2017; Talukdar et al., 2016), without inducing mitogenesis or hypoglycemia in rodents or monkeys.”
Direct activation of the fibroblast growth factor-21 pathway in overweight and obese cats
Brinker, E. J., Towns, T. J., Watanabe, R., Ma, X., Bashir, A., Cole, R. C., Wang, X., & Graff, E. C. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1072680 · Cited by 4
“Once FGF21 was discontinued in the cats, we observed an immediate and steady return to baseline body weight, similar to what was noted during the post-treatment period in non-human primates (11, 46, 50).”
BackgroundResultInfluentialRETRACTED ARTICLE: Relationship between the development of hyperlipidemia in hypothyroidism patients
Su, X., Chen, X., & Wang, B. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07423-z · Cited by 3
RetractedLü, C., Jin, L., Bi, J., Jin, H., You, X., Peng, L., Fan, H., Wang, H., Wang, L., Fan, Z., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1176136 · Cited by 2
“FGF-21 has been shown to significantly reduce blood sugar levels and body weight by regulating carbohydrate and fat homeostasis in diabetic or obese animal models (Kharitonenkov et al., 2007; Adams et al., 2013; Gaich et al., 2013; Markan and Potthoff, 2016; BonDurant et al., 2017; Kharitonenkov and DiMarchi, 2017; St…”
BackgroundFibroblast Growth Factor 21 as a Regulator of Energy Metabolism in the Liver and Adipose Tissue
Matikainen, N., & Söderlund, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816093-0.00013-6 · Cited by 2
Matsui, M., Kosaki, K., Akazawa, N., Tanahashi, K., Kuro‐o, M., & Maeda, S. (2019) · The Journal of Physical Fitness and Sports Medicine · doi:10.7600/jpfsm.8.195 · Cited by 2
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00003-2 · Cited by 2
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00004-4 · Cited by 2
Capito, F., Wong, T. H., Faust, C., Brand, K., Dittrich, W., Sommerfeld, M. R., Tiwari, G., & Langer, T. (2024) · Engineering in Life Sciences · doi:10.1002/elsc.202400019 · Cited by 1
Gorse, K., Snyder, K. L., & Jackson, T. C. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110529 · Cited by 1
Chetana, S., & Kalyani, B. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10079-3 · Cited by 1
“LY2405319 is an engineered FGF21 variant, was found to be effective in decreasing mean non-fasted blood glucose concentrations in diabetic rhesus monkeys [76 ].”
Jiménez, V., & Bosch, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch78 · Cited by 1
Li, P., Ye, H., Guo, F., Zheng, J., Shen, W., Xie, D., Shi, S., Zhang, Y., Fa, Y., & Zhao, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167616 · Cited by 1
Regulation of Metabolism by Hepatic OXPHOS: A Dissertation
Akie, T. E. (2015) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2388v
Jiang, X., Zou, Y., Opoku, Y. K., Liu, S., Wang, D., Kang, K., Li, D., & Ren, G. (2021) · Research Square · doi:10.21203/rs.3.rs-405082/v1
Development of a fibroblast growth factor 21 assay
Tamassia, G. V. (2017) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/62371
Jiang, X., Zou, Y., Opoku, Y. K., Liu, S., Wang, D., Kang, K., Li, D., & Ren, G. (2021) · Research Square · doi:10.21203/rs.3.rs-405082/v2
Endocrine fibroblast growth factors in domestic animals
Brinker, E. J., Hardcastle, M., Dittmer, K. E., & Graff, E. C. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106872
Insulin-sensitizing effects of fibroblast growth factor-21 in underfed sheep
dos Santos, A. C. R., McGuckin, M. M., Giesy, S. L., & Boisclair, Y. R. (2025) · Journal of Animal Science · doi:10.1093/jas/skaf217
WU, C.-T. (2024) · eScholarship (California Digital Library)
Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
Carbinatti, T. (2024) · theses.fr (ABES) · doi:10.70675/5d147ab4zad37z4f6bzac51z32a08efeaa51
Leung, H.-K., Tan, G.-J., Wong, W., Khamis, F., Zain, S. M., & Chan, W. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.20
Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging
Salmón‐Gómez, L., Keipert, S., Catalán, V., Rodríguez, A., Becerril, S., Frühbeck, G., & Gómez‐Ambrosi, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00627-w
Metadata
- Authors
- Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A.
- Affiliations
- Eli Lilly (United States) (US)
- University of South Florida (US)
- Corresponding author
- Kharitonenkov, Alexei
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-06-18
- Volume
- 8
- Issue
- 6
- Pages
- e65763
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3688819
- OpenAlex
- W1972717747
- Cited by
- 169
- References
- 24
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 19 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 8 · 2019: 12 · 2018: 10 · 2017: 17 · 2016: 12 · 2015: 22 · 2014: 11 · 2013: 3
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21 analogues, FGF21, type 2 diabetes, rhesus monkeys, glycemic control, lipid lowering, adiponectin, leptin, adipose tissue, insulin
- MeSH terms
- Animals, Blood Glucose, Energy Intake, Diabetes Mellitus, Experimental, Dose-Response Relationship, Drug, Fibroblast Growth Factors, Insulin, Macaca mulatta, Weight Loss, Disease Progression, Adipokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.